drugset / Trial / NCT06885034

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

NCT06885034

Phase 1/2 Recruiting 451 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will check how well a new medicine, GSK5764227, works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.

Timeline

Start
2025-06-11
Primary completion
2028-01-10
Completion
2029-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-20093 Other / unclassified